Table 1.
Patient characteristics.
| Total (n = 43) | Chemotherapy naive (n = 21) | Post docetaxel (n = 22) | p Value | |
|---|---|---|---|---|
| Age (years) | 74 | 76 | 73 | |
| Median (IQR) | (70–80) | (69–81) | (72–77) | 0.532 |
| Gleason score, n (%) | ||||
| <8 | 15 (38.5) | 12 (60.0) | 3 (15.8) | |
| ≥8 | 24 (61.5) | 8 (40.0) | 16 (84.2) | 0.005 |
| Unknown/missing | 4 | 1 | 3 | |
| Bone mts, n (%) | ||||
| No | 8 (18.6) | 5 (23.8) | 3 (13.6) | |
| Yes | 35 (81.4) | 16 (76.2) | 19 (86.4) | |
| <6 | 14 | 3 | 11 | |
| >6 | 21 | 13 | 8 | 0.514 |
| Visceral mts, n (%) | 9 (20.9) | 2 (9.5) | 7 (31.8) | 0.076 |
| Liver mts, n (%) | 2 (4.6) | 1 (4.7) | 1 (4.5) | 0.973 |
| Lymph node mts, n (%) | 20 (46.5) | 11 (52.4) | 9 (40.9) | 0.456 |
| Baseline PSA (ng/mL) | 40.54 | 32.76 | 54.05 | |
| Median (IQR) | (10.17–81.39) | (1.34–403.50) | (11.44–123.40) | 0.174 |
| Baseline LDH (U/L) | 168 | 167 | 177 | 0.449 |
| Median (IQR) | (151–201) | (145–198) | (157–208) | |
| Baseline ALP (IU/L) | 98 | 96 | 103 | 0.449 |
| Median (IQR) | (85–133) | (87–121) | (71–133) | |
| Baseline haemoglobin (g/dL) | 13.9 | 14.0 | 13.1 | 0.0003 |
| Median (IQR) | (13.2–14.2) | (14.0–14.6) | (12.2–13.9) | |
| Baseline albumin (g/dL) | 4.1 | 4.1 | 3.9 | 0.220 |
| Median (IQR) | (3.8–4.2) | (3.9–4.3) | (3.5–4.1) | |
| Baseline NLR (n (%)) | ||||
| <3 | 23 (53.5) | 13 (61.9) | 10 (45.5) | |
| ≥3 | 20 (46.5) | 8 (38.1) | 12 (54.5) | 0.285 |
ALP alkaline phosphatase, IQR interquartile range, LDH lactate dehydrogenase, mts metastasis, n number, NLR neutrophil-to-lymphocyte ratio, PSA prostate-specific antigen.